ArticleChemMedChem2026
A Nitroreductase-Activatable Lapachol Against Bacillus subtilis Unveils Antimicrobial Specificity.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Lapachol is a natural product with antimicrobial activity. Though promising for combating antimicrobial resistance, lapachol has toxicity to mammalian cells, which will cause severe side effects in vivo. To mitigate this, we developed alapachol prodrug which is dependent on the action of nitroreductase-an enzyme expressed in bacteria but not healthy mammalian cells. We observed release of lapachol in vitro by purified nitroreductase and in the gram-positive bacterial strain, Bacillus subtilis. Colony formation assays in Bacillus subtilis indicated release of lapachol, achieving comparable levels of toxicity as free lapachol. Lastly, minimal toxicity of our prodrug was observed in mammalian cell culture, demonstrating a >10-fold selectivity for bacteria over healthy mammalian cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.